DUVAX Vaccine Study for Alzheimer's Disease
DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau
- Age
- 40 – 65
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 24 (estimated)
- Sponsor
- Nuravax, Inc. · Industry
This trial is looking for healthy adults aged 40-65 to test a new vaccine for Alzheimer's disease. Participants will receive either the vaccine or a placebo shot and will be monitored for safety and immune response.
You may be able to join if
- I am a healthy male or non-pregnant, non-lactating female between 40 and 65 years old.
- My BMI is between 18.0 and 32.0.
- I have no significant medical issues.
- I can provide signed informed consent.
- If I am a woman of childbearing potential, I will have a negative pregnancy test and use effective contraception.
- If I am a man, I am vasectomized or will use condoms and not donate sperm during the study.
You may not be able to join if
- I have a serious medical or psychiatric illness.
- I have abnormalities in my MRI scan.
- I have significant lab test abnormalities or tested positive for certain viruses.
- I have uncontrolled blood pressure or abnormal heart rate.
- I have had a serious illness, surgery, or used an investigational drug in the last 30 days.
- I have had prior amyloid-beta or tau immunotherapy in the past year.
- I take immunosuppressive agents or chronic anticoagulants.
- I have a history of severe vaccine reactions, autoimmune disease, or significant allergies.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThis Phase 1 study will test the safety and immune response of the investigational vaccine DUVAX in healthy adults. Participants will be randomly assigned to receive either DUVAX or placebo by intramuscular injection. The study will evaluate how well the vaccine is tolerated and whether it produces antibodies against Alzheimer's disease-related proteins.
Loading trial locations…
No contact information available.